Outlook Therapeutics Inc
F:41O
Outlook Therapeutics Inc
F:41O
Price:
0.53
EUR
-0.56%
Market Closed
Market Cap:
€23.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Outlook Therapeutics Inc
F:41O
|
US |
|
Koninklijke Ahold Delhaize NV
AEX:AD
|
NL |
|
4DMedical Ltd
ASX:4DX
|
AU |
|
Biotalys NV
XBRU:BTLS
|
BE |
|
A
|
AXA SA
F:AXAA
|
FR |
|
Abercrombie & Fitch Co
NYSE:ANF
|
US |
|
Lumen Technologies Inc
F:CYTH
|
US |
|
Sherwin-Williams Co
NYSE:SHW
|
US |
|
Cyber_Folks SA
F:0K0
|
PL |
|
Persol Holdings Co Ltd
OTC:TEMPF
|
JP |
|
Dermapharm Holding SE
OTC:DMPHF
|
DE |
|
Hackett Group Inc
NASDAQ:HCKT
|
US |
|
N
|
Newmont Corporation
TSX:NGT
|
US |
|
O
|
Oriental Land Co Ltd
OTC:OLCLY
|
JP |
|
J
|
J. Front Retailing Co Ltd
OTC:JFROF
|
JP |
|
Public Storage
NYSE:PSA
|
US |
|
Indoritel Makmur Internasional Tbk PT
IDX:DNET
|
ID |
|
Mitsui & Co Ltd
OTC:MITSF
|
JP |
|
B
|
Bilfinger Se
DUS:GBF
|
DE |
|
Bilfinger Se
XETRA:GBF
|
DE |
|
S
|
Samsung Electro-Mechanics Co Ltd
KRX:009155
|
KR |
|
STERIS plc
NYSE:STE
|
IE |
| Metric | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| 9.1m | 2.4m | 3.2m | 1.7m | 8m | 12.5m | 14.5m | 17.4m | 23.4m | — | |
| 9.1m | 2.4m | 3.2m | 1.7m | 8m | 12.5m | 14.5m | 17.4m | — | — | |
| — | — | — | — | — | — | — | — | 23.4m | — | |
| 4.3m | — | — | — | — | — | — | — | — | — | |
| 20k | — | — | — | — | — | — | — | — | — | |
| 4.3m | — | — | — | — | — | — | — | — | — | |
| 1.8m | 3.3m | 719k | 1.6m | 5.5m | 5.4m | 7m | 10.1m | 7.6m | 12m | |
| 15.2m | 5.7m | 3.9m | 3.3m | 13.5m | 17.9m | 21.5m | 27.5m | 31m | 27m | |
| 17.8m | 18.7m | 16.1m | 18.5m | 3.2m | 494k | 275k | 70k | 26k | 270k | |
| 17.8m | 18.7m | 16.1m | 18.5m | 3.2m | 494k | 275k | 70k | — | — | |
| (3.6m) | (6m) | (8.6m) | (11.7m) | (1.1m) | (740k) | (904k) | (1.1m) | — | — | |
| — | — | — | — | — | 900k | 854k | 805k | 794k | 690k | |
| 2.1m | 1.1m | 740k | 491k | 457k | 394k | 175k | 132k | 501k | 440k | |
| 35m | 25.4m | 20.7m | 22.3m | 17.1m | 19.7m | 22.8m | 28.5m | 32.3m | 29m | |
| 11.6m | 5.1m | 11m | 3.6m | 2.3m | 2.4m | 2.2m | 3.5m | 6.6m | 8m | |
| 5.9m | 6.1m | 7.3m | 6.5m | 4.6m | 7.9m | 1.8m | 3.5m | 2.7m | 3.3m | |
| 0 | 0 | 0 | 13.2m | 6.7m | 0 | 0 | 0 | 0 | 0 | |
| 15.8m | 6.2m | 5m | 5.2m | 4.8m | 3.7m | 931k | 10.9m | 35.6m | 29m | |
| 3.7m | 3.1m | 5.4m | 3.6m | 1.9m | 1.9m | 1.9m | 1.9m | 1.9m | 1.9m | |
| 2m | 1.2m | 3.1m | 1.7m | — | — | — | — | — | — | |
| 37m | 20.4m | 28.7m | 32m | 20.3m | 15.9m | 6.8m | 19.7m | 46.7m | 43m | |
| 6.1m | 2.6m | 13.4m | 3.6m | 3.4m | 947k | 10.9m | 4k | 0 | 0 | |
| 1m | — | — | — | — | — | — | — | — | — | |
| 19.4m | 7.6m | 9.3m | 7.5m | 4.2m | 71k | 550k | 57k | 6k | 59m | |
| 63.6m | 30.6m | 51.5m | 43.1m | 27.9m | 16.9m | 18.2m | 19.8m | 46.7m | 102m | |
| 65.5m | 228k | 3.2m | 5.5m | 5.6m | 1.3m | 1.8m | 2.3m | 2.6m | 240k | |
| (94.1m) | (147.4m) | (186.2m) | (216.3m) | (254.5m) | (289.7m) | (342.9m) | (408.9m) | (467.9m) | (543m) | |
| 0 | 142m | 152.3m | 190m | 238.1m | 291.3m | 345.7m | 415.4m | 450.9m | 470m | |
| (28.6m) | (5.2m) | (30.7m) | (20.8m) | (10.8m) | 2.8m | 4.6m | 8.7m | (14.4m) | (73m) | |
| 35m | 25.4m | 20.7m | 22.3m | 17.1m | 19.7m | 22.8m | 28.5m | 32.3m | 29m | |
| 143k | 143k | 156k | 451k | 1.4m | 6.4m | 8.8m | 11.4m | 13m | 24m | |
| — | — | 33k | 60k | 66k | 0 | 0 | — | — | — |
A cash-generative biotech transitioning from legacy MS to acquired growth platforms
A rapidly scaled RNAi platform moving from R&D losses to product profitability
A global oncology platform moving from costly R&D expansion toward scalable profitability
A pre-commercial oncology platform funded by escalating losses and repeated capital raises
Continue 41O Research
Other Outlook Therapeutics Inc listings:
